December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
June 2016 in “Indian Journal of Pharmacy Practice” Stopping fluvoxamine can reverse hair loss caused by the drug.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
42 citations
,
September 2012 in “PLoS ONE” Bezafibrate treatment improved skin and spleen health in aging mice but didn't extend lifespan.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
June 2016 in “Annals of the rheumatic diseases” Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.
September 2004 in “Fertility and Sterility” Norplant implants lower some androgen levels but don't significantly change sexual function.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.
2 citations
,
May 2023 in “The Journal of Immunology” NXC736 significantly reduced hair loss in mice with alopecia areata.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
Ovulation inhibitors effectively treat menstrual issues and improve fertility but can have side effects.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
February 2016 in “Annals of the Rheumatic Diseases” All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
June 2025 in “BMJ Case Reports” Axitinib treatment turned a man's grey hair back to black.
64 citations
,
May 2000 in “International Journal of Dermatology” Thalidomide improved lupus symptoms but caused nerve damage in some patients.
36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
12 citations
,
September 2012 in “Alcohol and Alcoholism” Alcohol in teen years leads to more adult drinking, finasteride doesn't help.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
1 citations
,
June 2001 in “Annals of Internal Medicine” Troglitazone increases subcutaneous fat in lipodystrophy patients.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
April 2026 in “Journal of Cosmetic Dermatology” 4 citations
,
November 2021 in “Journal of The American Academy of Dermatology” Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
1 citations
,
May 2025 in “Frontiers in Medicine” Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
40 citations
,
September 2014 in “Journal of cosmetic and laser therapy” Transepidermal drug delivery effectively treated areata alopecia with minimal side effects.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.